bioAffinity Technologies vs Quantum-Si
bioAffinity Technologies reported revenue of $6 million in fiscal 2025, 2.6 times Quantum-Si's $2 million in fiscal 2025. bioAffinity Technologies' revenue fell 34.2% in its latest year, and Quantum-Si's fell 20.3%. bioAffinity Technologies had an operating margin of -171.6%, against -4766.0% at Quantum-Si. Free cash flow was −$9 million at bioAffinity Technologies and −$97 million at Quantum-Si.
Side by side
| bioAffinity Technologies | Quantum-Si | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6M | $2M |
| Revenue growth | −34.2% | −20.3% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | 47.3% |
| Operating margin | −171.6% | −4,766.0% |
| Net margin | −242.0% | −4,160.1% |
| Free cash flow | −$9M | −$97M |
| Free cash flow margin | −152.4% | −3,991.5% |
| Return on capital | −400.1% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 325.8% | 38.1% |
| Last close | $1.85 | $1.07 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.0 million, sold $1.2 million | bought $564,396, sold $494,746 |
| Piotroski F-score | 3 of 8 | 1 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
bioAffinity TechnologiesQuantum-Si
Operating margin
Percent of revenue
bioAffinity TechnologiesQuantum-Si
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
bioAffinity TechnologiesQuantum-Si
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the bioAffinity Technologies and Quantum-Si pages.